11:29 AM
Dec 05, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Hemophilia

Cell culture and mouse studies suggest an engineered mutant Factor VIIa/Tissue Factor complex could help treat hemophilia A. The mutant complex consisted of Factor VIIa and soluble TF harboring Q64C and G109C mutations, respectively, which introduced a stabilizing cystine bridge...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >